Watch as Dr. Michael Elliott, Chief of Neurology at the Swedish Neuroscience Institute, shares his personal experiences and best practices for the diagnosis and management of ALS.
Enroll in the ALS Care Locator
MEDICAL PRACTICE
RADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
ALS Expert Video Library
Learn more about RADICAVA® (edaravone) for the treatment of ALS through a series of educational videos.
Hear From Your Peers
Experienced neurologists provide their insights for considering RADICAVA treatment that has been prescribed by 2500+ US HCPs since August 2017.1,a (see footnote)
Providers are paid consultants.
Featured video—Experiences of an ALS Expert, Featuring Dr. Michael Elliott
Experiences of an ALS Expert, Featuring Dr. Michael Elliott
Dosing and administration of RADICAVA ORS® (edaravone)
Learn about the dosing and administration of RADICAVA ORS®, in this video featuring Dr. Michael Elliott.
Dosing and administration of RADICAVA ORS® (edaravone)
The Safety and Efficacy of RADICAVA® IV (edaravone) and RADICAVA ORS®
Watch Dr Michael Elliott, Chief of Neurology for the Swedish Neuroscience Institute, provide a clinical overview of the Efficacy and Safety of RADICAVA® IV and RADICAVA ORS®.
The Safety and Efficacy of RADICAVA® IV (edaravone) and RADICAVA ORS®
Nationwide Webcast Video Discussion About a Treatment in ALS
Stanley H. Appel, MD, and Gary L. Pattee, MD, discuss RADICAVA ORS® data and their thoughts on what oral treatment means to patients.
Nationwide Webcast Video Discussion About a Treatment in ALS
The Efficacy of RADICAVA®
Said Beydoun, MD, FAAN, discusses clinical trial results of RADICAVA®, his use of the ALSFRS-R with his patients, and the challenges that have faced previous ALS clinical trials and how newer clinical trials are addressing them.
The Efficacy of RADICAVA®
Providers are paid consultants.
See patient and caregiver experiences with RADICAVA.
Learn more
Review educational webinars for ALS patients that may be appropriate for your patients.
Learn more
Add your practice to our ALS Care Locator.
Presentations
A panel of ALS experts discuss the benefits, risks, and appropriate uses of RADICAVA.
Providers are paid consultants.
Dr. Trevor J. Resnick
Clinical Professor, Department of Neurology
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida
Dr. Carlayne Jackson
University of Texas Health Science Center
San Antonio, Texas
Dr. Jonathan Katz
California Pacific Medical Center
San Francisco, California
Efficacy and Safety
Hear about primary efficacy endpoint data and safety information from the pivotal trial of RADICAVA®.
Efficacy and Safety
Explore detailed results of the pivotal trials that were discussed.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of December 2024. Not independently verified. Return to content
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings 2. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.
